DHT and Hair Loss: How It Works and What You Can Do About It
DHT and Hair Loss: How It Works and What You Can Do About It
If you have researched hair loss at all, you have encountered DHT. It appears in almost every explanation of male pattern baldness — and increasingly in discussions of female hair thinning as well. Yet most summaries of DHT stop at "it causes hair loss" without explaining how, which makes it hard to evaluate what treatments actually address the problem and which ones are marketing noise.
This guide goes deeper: the biochemistry of DHT, why it affects some follicles and not others, what "blocking DHT" actually means in a topical context, and the realistic expectations for non-pharmaceutical approaches available without a prescription in Singapore.
Quick Answer
DHT (dihydrotestosterone) is a potent androgen produced when 5-alpha reductase converts testosterone in the scalp. It binds to androgen receptors in genetically susceptible hair follicles and progressively shortens the growth cycle — producing finer, shorter hair until the follicle is dormant. It drives 95% of male pattern baldness and contributes to a subset of female hair thinning. Topical approaches that reduce scalp inflammation and support follicle signalling can slow DHT-driven miniaturisation without systemic hormone effects.
What DHT Is and Where It Comes From
DHT is an androgen — a class of hormones that includes testosterone — and is approximately five times more potent than testosterone at the androgen receptor. It is synthesised primarily from testosterone through the action of the enzyme 5-alpha reductase (5-AR), which exists in two forms in humans: Type 1 (found mainly in the skin and liver) and Type 2 (found in the scalp, prostate, and other androgen-sensitive tissues).
DHT plays important roles in normal male development — it is responsible for the development of male external genitalia in utero and drives sexual maturation during puberty. The problem for scalp hair is that the same receptor that DHT activates in other tissues also exists in hair follicles — and in genetically susceptible follicles, activation by DHT triggers miniaturisation rather than growth.
Critically, systemic DHT levels do not predict pattern hair loss severity. A man with relatively low testosterone can still experience aggressive baldness if his follicles have high receptor sensitivity. Conversely, men with high testosterone levels may retain their hair if their follicles carry low androgen receptor density in susceptible zones. The variable is local receptor sensitivity, not circulating hormone levels.
How DHT Miniaturises Hair Follicles
| Stage | What Happens | Visible Effect |
|---|---|---|
| DHT binds to receptor | Androgen receptor in follicle activated; gene expression altered | No immediate visible change |
| Anagen phase shortens | Each growth cycle produces hair for less time | Hairs gradually fail to reach full length |
| Follicle shrinks | Dermal papilla and follicle matrix reduce in size | Finer, lighter hairs; smaller hair shaft diameter |
| Vellus conversion | Terminal follicle becomes vellus follicle | Visible scalp through very fine peach-fuzz hair |
| Follicle dormancy | Follicle ceases producing hair; dermal papilla may still survive | Bald scalp; follicle potentially revivable if not fully fibrotic |
This is why pattern hair loss is called "miniaturisation" rather than simply loss — the follicle does not suddenly disappear. It degrades gradually across many growth cycles. Understanding the hair growth cycle makes this progression clearer: each anagen phase shortens incrementally, producing years of gradual visible change before a follicle is truly dormant.
DHT-driven miniaturisation is slow and invisible for years. Hair looks normal until enough follicles have miniaturised that the cumulative effect becomes visible — often simultaneously at the temples and crown. This creates the impression of sudden hair loss when the biological process has been ongoing for years. Earlier action than most men think necessary is the right call.
DHT in Women: A Different Picture
DHT is present in women too — at lower levels — and plays a role in female androgenetic alopecia. However, female pattern hair loss presents differently: diffuse thinning across the crown with preservation of the frontal hairline, rather than the M-shaped recession seen in men. This is partly because women have higher levels of aromatase, an enzyme that converts androgens to oestrogens in the scalp, providing partial protection.
For women experiencing hormonal hair loss, DHT is one contributor alongside oestrogen fluctuation, progesterone changes, and thyroid function. The approach to scalp support is similar — but the diagnostic picture is more complex and often warrants medical assessment.
Approaches to Addressing DHT-Driven Hair Loss
Pharmaceutical: Systemic DHT Blockade
Finasteride (Propecia) and dutasteride block 5-alpha reductase, reducing DHT production throughout the body. They are clinically effective for androgenetic alopecia — studies show meaningful reduction in hair loss progression and some regrowth in a proportion of men. They require a prescription, continuous use, and carry a documented side-effect profile including sexual dysfunction reported in a subset of users. See the Singapore comparison guide to minoxidil, finasteride, and exosome care for a detailed breakdown.
Topical: Scalp Environment and Follicle Signalling
Topical approaches work differently from systemic 5-AR inhibitors. Rather than blocking DHT production across the body, they address the scalp conditions that amplify DHT damage — inflammation, oxidative stress, impaired follicle signalling — and support the follicle's own repair and growth processes.
Phyto-exosome technology operates at the cell-signalling level. Plant-derived exosomes carry proteins and RNA that deliver growth signals to follicle stem cells, supporting the anagen phase and reducing the rate at which DHT-stressed follicles miniaturise. The science of exosome technology for hair loss explains the mechanism in full. It is complementary to pharmaceutical approaches and suitable as a standalone for men seeking drug-free support.
The foundation is scalp cleansing. A sulfate-free hair loss shampoo removes the sebum, pollution, and inflammatory triggers that compound DHT damage at the follicle level. A clean, healthy scalp environment improves the effectiveness of any leave-on active — whether pharmaceutical or non-pharmaceutical.
Many men use both approaches simultaneously. Finasteride reduces DHT systemically; a phyto-exosome leave-on treatment supports follicle signalling and scalp health locally. The two mechanisms are complementary. If you are already on medication, adding a scalp homecare routine improves the environment that medication is working in.
Frequently Asked Questions
Does higher DHT always mean more hair loss?
Not necessarily. The variable is follicle sensitivity to DHT, not DHT level alone. Men with high androgen receptor sensitivity in susceptible follicles can experience significant pattern loss even with modest DHT levels. Men with lower receptor sensitivity may retain more hair despite higher DHT.
Can you reduce DHT naturally?
Some evidence suggests that zinc and saw palmetto may modestly inhibit 5-alpha reductase activity, though at much lower potency than finasteride. Reducing inflammatory and oxidative scalp conditions does not lower DHT levels but reduces DHT's amplified effect on stressed follicles. Diet, sleep, and stress management support overall follicle health.
Can DHT hair loss be reversed without medication?
In early-stage miniaturisation — where follicles are still producing fine vellus hair — consistent topical support with phyto-exosome technology and a healthy scalp environment can produce visible improvement. Advanced miniaturisation with dormant follicles is much harder to reverse without clinical intervention.
How long does it take for DHT to cause noticeable hair loss?
The miniaturisation process typically takes years to become visible — each hair growth cycle is 2–6 years in healthy follicles. Loss becomes noticeable once a sufficient proportion of follicles in a zone have miniaturised, creating the cumulative visible effect. Most men have been experiencing miniaturisation for 3–5 years before they notice visible recession.
Is DHT hair loss different from stress hair loss?
Yes. DHT hair loss (androgenetic alopecia) follows a pattern — temples, crown — and progresses gradually over years. Stress hair loss (telogen effluvium) causes diffuse shedding across the whole scalp, typically appearing 2–3 months after a triggering event, and largely resolves once the trigger is removed. Many people experience both simultaneously, which compounds apparent severity.
Does minoxidil block DHT?
No. Minoxidil is a vasodilator — it increases blood flow to follicles and prolongs the anagen phase, but it does not affect DHT levels or 5-alpha reductase activity. This is why minoxidil requires continuous use and why results diminish when it is stopped — the underlying DHT sensitivity is unchanged.
The Bottom Line
DHT drives the overwhelming majority of male hair loss — and the biology is well-established. It does so by progressively miniaturising susceptible follicles through a predictable receptor-binding cascade. The key variables are follicle sensitivity (genetic) and scalp environment (partly modifiable).
For men who want a drug-free approach, phyto-exosome technology and sulfate-free scalp care address the environmental amplifiers of DHT damage and support the follicle signalling that opposes miniaturisation. For men with more aggressive loss, these approaches complement rather than replace pharmaceutical options. In either case, earlier intervention means more active follicles to work with.
Related reading: men's DHT and pattern loss guide · male pattern baldness stages and solutions · minoxidil side effects Singapore
Take the Next Step
Featured by Singapore Airlines SilverKris · Business Traveller Magazine · Winner: Best Hair Growth & Strengthening Ampoule — Editors' Choice Award · 100% drug-free